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Abstract
Purpose Cis-acting regulatory SNPs resulting in differen-
tial allelic expression (DAE) may, in part, explain the
underlying phenotypic variation associated with many
complex diseases. To investigate whether common variants
associated with DAE were involved in breast cancer sus-
ceptibility among BRCA1 and BRCA2 mutation carriers, a
list of 175 genes was developed based of their involvement
in cancer-related pathways.
Methods Using data from a genome-wide map of SNPs
associated with allelic expression, we assessed the association
of*320SNPs located in the vicinity of these geneswith breast
and ovarian cancer risks in 15,252 BRCA1 and 8211 BRCA2
mutation carriers ascertained from 54 studies participating in
the Consortium of Investigators of Modifiers of BRCA1/2.
Results We identified a region on 11q22.3 that is signifi-
cantly associated with breast cancer risk in BRCA1 muta-
tion carriers (most significant SNP rs228595 p = 7 9
10-6). This association was absent in BRCA2 carriers
(p = 0.57). The 11q22.3 region notably encompasses
genes such as ACAT1, NPAT, and ATM. Expression
quantitative trait loci associations were observed in both
normal breast and tumors across this region, namely for
ACAT1, ATM, and other genes. In silico analysis revealed
some overlap between top risk-associated SNPs and rele-
vant biological features in mammary cell data, which
suggests potential functional significance.
Conclusion We identified 11q22.3 as a new modifier locus
in BRCA1 carriers. Replication in larger studies using
estrogen receptor (ER)-negative or triple-negative (i.e.,
ER-, progesterone receptor-, and HER2-negative) cases
could therefore be helpful to confirm the association of this
locus with breast cancer risk.
Keywords Breast cancer  Genetic modifiers  Differential
allelic expression  Genetic susceptibility  Cis-regulatory
variants  BRCA1 and BRCA2 mutation carriers
Introduction
Pathogenic mutations in the BRCA1 and BRCA2 genes
substantially increase a woman’s lifetime risk of develop-
ing breast and ovarian cancers [1–4]. These risks vary
significantly according to (a) age at disease diagnosis in
carriers of identical mutations, (b) the cancer site in the
individual who led to the family’s ascertainment, (c) the
degree of family history of the disease [1, 4, 5], and (d) the
22 City of Hope Clinical Cancer Genomics Community
Research Network, 1500 East Duarte Road, Duarte,
CA 91010, USA
23 Unite´ de Pre´vention et d’Epide´miologie Ge´ne´tique, Centre
Le´on Be´rard, 28 rue Lae¨nnec, 69373 Lyon, France
24 Division of Cancer Prevention and Genetics, Istituto Europeo
di Oncologia (IEO), Via Ripamonti 435, 20141 Milan, Italy
25 Department of Medicine, Abramson Cancer Center, Perelman
School of Medicine at the University of Pennsylvania, 3400
Civic Center Boulevard, Philadelphia, PA 19104, USA
26 Department of Clinical Genetics, Royal Devon & Exeter
Hospital, Exeter EX1 2ED, UK
27 Service de Ge´ne´tique Oncologique, Institut Curie, 26 rue
d’Ulm, 75248 Paris Cedex 05, France
28 Department of Medicine, Huntsman Cancer Institute, 2000
Circle of Hope, Salt Lake City, UT 84112, USA
29 Section of Genetic Oncology, Department of Laboratory
Medicine, University and University Hospital of Pisa, Pisa,
Italy
30 Unite´ de recherche en sante´ des populations, Centre des
maladies du sein Descheˆnes-Fabia, Hoˆpital du Saint-
Sacrement, 1050 chemin Sainte-Foy, Quebec, QC G1S 4L8,
Canada
31 Departments of Pediatrics and Medicine, Columbia
University, 1150 St. Nicholas Avenue, New York, NY 10032,
USA
32 Center for Medical Genetics, Ghent University, De Pintelaan
185, 9000 Ghent, Belgium
33 Division of Population Science, Fox Chase Cancer Center,
333 Cottman Avenue, Philadelphia, PA 19111, USA
34 Department of Clinical Genetics, South Glasgow University
Hospitals, Glasgow G51 4TF, UK
35 Molecular Oncology Laboratory, Hospital Clinico San
Carlos, IdISSC (El Instituto de Investigacio´n Sanitaria del
Hospital Clı´nico San Carlos), Martin Lagos s/n, Madrid,
Spain
36 Oncogenetics Group, Vall d’Hebron Institute of Oncology
(VHIO), Vall d’Hebron University Hospital, Clinical and
Molecular Genetics Area, Passeig Vall d’Hebron 119-129,
08035 Barcelona, Spain
37 Department of Population Sciences, Beckman Research
Institute of City of Hope, Duarte, CA, USA
38 Cancer Bioimmunotherapy Unit, Department of Medical
Oncology, Centro di Riferimento Oncologico, IRCCS
(Istituto Di Ricovero e Cura a Carattere Scientifico) National
Cancer Institute, Via Franco Gallini 2, 33081 Aviano, PN,
Italy
39 University of Queensland Diamantina Institute, Translational
Research Institute, Brisbane, QLD, Australia
40 Cancer Genetics Laboratory, Department of Genetics,
University of Pretoria, Private Bag X323, Arcadia 0007,
South Africa
Breast Cancer Res Treat
123
type and location of BRCA1 and BRCA2 mutations [6].
These observations suggest that other factors, including
lifestyle/hormonal factors [7] as well as other genetic fac-
tors, modify cancer risks in BRCA1 and BRCA2 mutation
carriers. Direct evidence for such genetic modifiers of risk
has been obtained through the association studies per-
formed by the Consortium of Investigators of Modifiers of
BRCA1/2 (CIMBA), which have shown that several com-
mon breast cancer susceptibility alleles identified through
population-based genome-wide association studies
(GWASs) are also associated with breast cancer risk among
BRCA1 and BRCA2 mutation carriers [8–10].
Global analysis of GWAS data has shown that the vast
majority of common variants associated with susceptibility
to cancer lie within genomic non-coding regions and are
predicted to account for cancer risk through regulation of
gene expression [11, 12]. A recent expression quantitative
trait loci (cis-eQTL) analysis for mRNA expression in 149
known cancer risk loci performed in five tumor types
(breast, colon, kidney, lung, and prostate) has shown that
approximately 30 % of such risk loci were significantly
associated with eQTLs present in at least one gene within
500 kb [13]. These results suggest that additional cancer
susceptibility loci may be identified through studying
genetic variants that affect the regulation of gene expres-
sion. In the present study, we selected genes of interest for
their known involvement in cancer etiology, identified 320
genetic variants in the vicinity of these genes with evidence
of differential allelic expression (DAE), and then
investigated the associations of these variants with breast
and ovarian cancer risks among BRCA1 and BRCA2
mutation carriers. These included variants in genes
involved in DNA repair (homologous recombination and
DNA interstrand crosslink repair), interaction with and/or
modulation of BRCA1 and BRCA2 cellular functions, cell
cycle control, centrosome amplification and interaction
with AURKA, apoptosis, ubiquitination, as well as known
tumor suppressors, mitotic kinases, and other kinases, sex
steroid action, and mammographic density.
Materials and methods
Subjects
All study participants were female carriers of a deleteri-
ous germline mutation in either BRCA1 or BRCA2 and
aged 18 years or older [14]. Fifty-four collaborating
CIMBA studies contributed a total of 23,463 samples
(15,252 BRCA1 mutation carriers and 8211 BRCA2
mutation carriers) to this study, including 12,127 with
breast cancer (7797 BRCA1 and 4330 BRCA2 carriers)
and 3093 with ovarian cancer (2462 BRCA1 and 631
BRCA2 carriers). The number of samples included from
each study is provided in Online Resource 1. The
recruitment strategies, clinical, demographic, and pheno-
typic data collected from each participant have been
previously reported [14].
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Ethics statement
BRCA1 and BRCA2 mutation carriers were recruited
through the CIMBA initiative, following approval of the
corresponding protocol by the Institutional Review Board
or Ethics Committee at each participating center (Online
Resource 2); written informed consent was obtained from
all study participants [8, 9].
SNP selection and differential allelic expression
SNP selection was performed by first identifying a list of 175
genes of interest involved in cancer-related pathways and/or
mechanisms. The list of genes was established by analyzing
published results and by using available public databases
such as the Kyoto encyclopedia of genes and genomes
(http://www.genome.jp/kegg/). Next, DAE SNPs located
within these gene regions were identified using previously
reported data on allelic expression cis-associations, derived
using (1) the lllumina Human1M-duo BeadChip for lym-
phoblastoid cell lines from Caucasians (CEU population)
(n = 53) [15], the Illumina Human 1M Omni-quad for pri-
mary skin fibroblasts derived from Caucasian donors
(n = 62) [13, 16], and the Illumina Infinium II assay with
Human 1.2M Duo custom BeadChip v1 for human primary
monocytes (n = 188) [17]. Briefly, 1000 Genomes project
data were used as a reference set (release 1000G Phase I v3)
for the imputation of genotypes from HapMap individuals.
Genotypes were inferred using algorithms implemented in
IMPUTE2 [18]. The unrelated fibroblast panel consisted of
31 parent–offspring trios, in which the genotypes of off-
spring were used to permit accurate phasing. Mapping of
each allelic expression trait was carried out by first normal-
izing allelic expression ratios at each SNP using a polyno-
mial method [19] and then calculating average phased allelic
expression scores across annotated transcripts, followed by
correlation of these scores to local (transcript ± 500 kb)
SNP genotypes in fibroblasts as described earlier [16]. A
total of 355 genetic variants were selected on the basis of
evidence of association with DAE in the selected 175 genes
(see Online Resource 3 for a complete list of SNPs and
genes). Following the selection process, SNPs were sub-
mitted for design and inclusion on a custom-made Illumina
Infinium array (iCOGS) as previously described [8, 9]. Fol-
lowing probe design and post-genotyping quality control,
316 and 317 SNPs were available for association analysis in
BRCA1 and BRCA2 mutation carriers, respectively. Geno-
typing and quality control procedures have been described in
detail elsewhere [8, 9].
Statistical analysis
Associations between genotypes and breast and ovarian
cancer risks were evaluated within a survival analysis
framework, using a one degree-of-freedom score test statistic
based on modeling the retrospective likelihood of the
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observed genotypes conditional on the disease phenotypes
[20, 21]. To estimate the magnitude of the associations
[hazard ratios (HRs)], we maximized the retrospective like-
lihood, which was parameterized in terms of the per-allele
HR. All analyses were stratified by country of residence and
using calendar year and cohort-specific incidence rates of
breast and ovarian cancers for mutation carriers. Given 320
tests, the cutoff value for significance after a Bonferroni
adjustment for multiple testing was p\ 1.5 9 10-4.
The associations between the genotypes and tumor
subtypes were evaluated using an extension of the retro-
spective likelihood approach that models the association
with two or more subtypes simultaneously [22].
Imputation was performed separately for BRCA1 and
BRCA2 mutation carriers to estimate genotypes for other
common variants across a ±50-kb region centered around
the 12 most strongly associated SNPs (following the NCBI
Build 37 assembly), using the March 2012 release of the
1000 Genomes Project as the reference panel and the
IMPUTE v.2.2 software [18]. In all analyses, only SNPs
with an imputation accuracy coefficient r2 [0.30 were
considered [8, 9].
Functional annotation
Publicly available genomic data were used to annotate the
SNPs most strongly associated with breast cancer risk at
locus 11q22.3. The following regulatory features were
obtained for breast cell types from ENCODE and NIH
Roadmap Epigenomics data through the UCSC Genome
Browser: DNase I hypersensitivity sites, chromatin hid-
den Markov modeling (ChromHMM) states, and histone
modifications of epigenetic markers, more specifically
commonly used marks associated with enhancers
(H3K4Me1 and H3K27Ac) and promoters (H3K4Me3
and H3K9Ac). To identify putative target genes, we
examined potential functional chromatin interactions
between distal and proximal regulatory transcription
factor-binding sites and the promoters at the risk loci,
using the chromatin interaction analysis by paired end tag
(ChiA-PET) and genome conformation capture (Hi-C, 3C,
and 5C) datasets downloaded from GEO and from 4D-
genome [23]. Maps of active mammary super-enhancer
regions in human mammary epithelial cells (HMECs)
were obtained from Hnisz et al. [24]. Enhancer–promoter
specific interactions were predicted from the integrated
method for predicting enhancer targets (IM-PETs) [25].
RNA-Seq data from ENCODE was used to evaluate the
expression of exons across the 11q22.3 locus in MCF7
and HMEC cell lines. For MCF7 and HMEC, alignment
files from 19 and 4 expression datasets, respectively,
were downloaded from ENCODE using a rest API
wrapper (ENCODExplorer R package) [26] in the bam
format and processed using metagene R packages [27] to
normalize in Reads per Millions aligned and to convert
into coverages.
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eQTL analyses
The influence of germline genetic variations on gene
expression was assessed using a linear regression model,
as implemented in the R library eMAP (http://www.bios.
unc.edu/*weisun/software.htm). An additive effect was
inferred by modeling subjects’ copy number of the rare
allele, i.e., 0, 1, or 2 for a given genotype. Only rela-
tionships in cis (defined as those for which the SNP is
located at \1 Mb upstream or downstream from the
center of the transcript) were investigated. The eQTL
analyses were performed on both normal and tumor breast
tissues (see Online Resource 4 for the list and description
of datasets, as well as the sources of genotype and
expression data). For all sample sets, the genotyping data
were processed as follows: SNPs with call rates\0.95 or
minor allele frequencies, MAFs (\0.05) were excluded, as
were SNPs out of Hardy–Weinberg equilibrium with
P\ 10-13. All samples with a call rate \80 % were
excluded. Identity by state was computed using the R
GenABEL package [28], and samples from closely related
individuals whose identity by state was lower than 0.95
were removed. The SNP and sample filtration criteria
were applied iteratively until all samples and SNPs met
the set thresholds.
Results
From the 175 genes selected for their involvement in
cancer-related pathways and/or mechanisms, we identified
a set of 355 genetic variants showing evidence of associ-
ation with DAE (see Online Resource 3 for the complete
list of genes and SNPs). Of those, 39 and 38 SNPs were
excluded because of low Illumina design scores, low call
rates, and/or evidence of deviation from Hardy–Weinberg
equilibrium (P value \10-7), for BRCA1 and BRCA2
analyses, respectively. A total of 316 and 317 SNPs (rep-
resenting 227 independent SNPs with a pairwise r2\0.1)
were successfully genotyped in 15,252 BRCA1 and 8211
BRCA2 mutation carriers, respectively. Association results
for breast and ovarian cancer risks for all SNPs are pre-
sented in Online Resource 5.
Breast cancer association analysis
Evidence of association with breast cancer risk (at
p\ 10-2) was observed for nine SNPs in BRCA1 mutation
carriers and three SNPs in BRCA2 mutation carriers
(Table 1). The strongest association with breast cancer risk
among BRCA1 carriers was observed for rs6589007,
located at 11q22.3 in intron 15 of the NPAT gene
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(p = 4.6 9 10-3) at approximately 54 kb upstream of the
ATM gene. Similar associations were observed for two
other highly correlated variants (r2[0.8) on chromosome
11, namely rs183459 (p = 5.7 9 10-3) also located within
NPAT and rs228592 (p = 5.5 9 10-3) located in intron 11
of ATM. No association was observed between SNPs at this
locus and breast cancer risk for BRCA2 carriers (Online
Resource 5).
The strongest evidence of association with breast cancer
risk in BRCA2 mutation carriers was observed for
Table 1 Associations with breast cancer risk in BRCA1 and BRCA2 mutation carriers for SNPs observed at p\ 10-2
Locations Positions SNPs Nearest
genes
Unaffected
(number)
Affected
(number)
Unaffected
(MAF)
Affected
(MAF)
HR* (95 % CI) p values
BRCA1 mutation carriers
1q42.13 227,308,416 rs11806633 CDC42BPA 7455 7797 0.07 0.06 1.128 (1.039–1.225) 4.8 9 10-3
2p23.2 28,319,320 rs6721310 BRE 7454 7793 0.33 0.33 1.064 (1.018–1.111) 5.4 9 10-3
2q11.2 100,019,496 rs2305354 REV1 7451 7796 0.44 0.45 1.057 (1.015–1.100) 7.1 9 10-3
4p15.33 14,858,341 rs1389999 CEBP 7454 7795 0.35 0.35 0.940 (0.901–0.982) 5.3 9 10-3
5q14.1 79,901,952 rs425463 DHFR,
MSH3
7430 7755 0.33 0.35 1.058 (1.013–1.105) 9.5 9 10-3
11q22.3 108,040,104 rs6589007 NPAT,
ACAT1,
ATM
7451 7797 0.41 0.42 1.062 (1.019–1.107) 4.6 9 10-3
11q22.3 108,089,197 rs183459 NPAT,
ATM
7447 7789 0.40 0.41 1.061 (1.018–1.105) 5.7 9 10-3
11q22.3 108,123,189 rs228592 ATM 7449 7792 0.42 0.41 1.061 (1.018–1.106) 5.5 9 10-3
12p13.33 986,004 rs7967755 WNK1,
RAD52
7454 7797 0.16 0.152 0.927 (0.876–0.980) 7.5 9 10-3
BRCA2 mutation carriers
6p22.1 28,231,243 rs9468322 NKAPL 3880 4329 0.04 0.05 1.235 (1.080–1.412) 4.2 9 10-3
8q11.21 48,708,742 rs6982040 PRKDC 3876 4327 0.006 0.002 0.497 (0.292–0.843) 2.7 9 10-3
16p13.3 1,371,154 rs2268049 UBE2I 3880 4325 0.14 0.16 1.116 (1.031–1.207) 4.5 9 10-3
CI confidence interval, HR hazard ratio, MAF minor allele frequency, SNP single-nucleotide polymorphism
* Hazard ratio per allele (one degree of freedom) estimated from the retrospective likelihood analysis
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rs6982040, located at 8q11.21 in intron 74 of the PRKDC
gene (p = 2.7 9 10-3). However, this variant had a very
low frequency in affected and unaffected individuals (MAF
values of 0.002 and 0.006, respectively). No association
was observed for this locus in BRCA1 carriers (Online
Resource 5).
Of the nine SNPs associated with breast cancer risk in
BRCA1 mutation carriers, three were primarily associated
with estrogen receptor (ER)-negative breast cancer:
rs11806633 at 1q42.13 in the CDC42BPA gene
(p = 9.0 9 10-3), rs6721310 at 2p23.2 in the BRE gene
(p = 3.0 9 10-3), and rs2305354 at 2q11.2 in the REV1
gene (p = 1.0 9 10-3), although the differences between
ER-positive and ER-negative disease associations were not
statistically significant (Table 2). Of the three BRCA2-as-
sociated loci, only rs9468322 at 6p22.1 was associated with
Table 2 Associations with breast cancer risk by tumor subtype in BRCA1 and BRCA2 mutation carriers
Locations Positions SNPs ER-positive ER-negative ER-diff
HR (95 % CI) p values HR (95 % CI) p values p-diff
BRCA1 mutation carriers
1q42.13 227,308,416 rs11806633 1.10 (0.90–1.33) 0.35 1.14 (1.03–1.25) 9.0 9 10-3 0.73
2p23.2 28,319,320 rs6721310 1.00 (0.88–1.09) 0.96 1.08 (1.04–1.15) 3.0 9 10-3 0.20
2q11.2 100,019,496 rs2305354 0.98 (0.91–1.10) 0.71 1.09 (1.03–1.13) 1.0 9 10-3 0.09
4p15.33 14,858,341 rs1389999 0.94 (0.85–1.04) 0.20 0.94 (0.89–0.99) 2.0 9 10-2 0.95
5q14.1 79,901,952 rs425463 1.04 (0.94–1.15) 0.48 1.07 (1.01–1.12) 1.6 9 10-2 0.67
11q22.3 108,040,104 rs6589007 1.08 (0.99–1.19) 9.8 9 10-2 1.06 (1.01–1.11) 2.0 9 10-2 0.66
11q22.3 108,089,197 rs183459 1.08 (0.99–1.19) 9.3 9 10-2 1.05 (1.00–1.11) 3.7 9 10-2 0.62
11q22.3 108,123,189 rs228592 1.08 (0.96–1.19) 9.7 9 10-2 1.06 (1.00–1.11) 3.4 9 10-2 0.64
12p13.33 986,004 rs7967755 0.96 (0.84–1.09) 0.54 0.92 (0.86–0.98) 1.0 9 10-2 0.56
BRCA2 mutation carriers
6p22.1 28,231,243 rs9468322 1.30 (1.12–1.51) 5.0 9 10-4 1.00 (0.72–1.40) 0.99 0.17
8q11.21 48,708,742 rs6982040 N/A N/A N/A N/A N/A
16p13.3 1,371,154 rs2268049 1.10 (1.01–1.21) 4.0 9 10-2 1.17 (0.98–1.39) 8.0 9 10-2 0.56
CI confidence interval, HR hazard ratio, SNP single-nucleotide polymorphism, N/A not available
* Hazard ratio per allele (one degree of freedom) estimated from the retrospective likelihood analysis
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ER-positive disease (p = 5.0 9 10-4), although the dif-
ferences in HRs between ER-positive and ER-negative
tumors were not statistically significant (Table 2).
Although evidence of association with breast cancer risk
was observed for the above-described loci in BRCA1 and
BRCA2 mutation carriers, none of these associations
reached significance after a Bonferroni adjustment for
multiple testing. Imputation using the 1000 Genomes data
(encompassing ± 50 kb centered on each of the 12 asso-
ciated variants, Online Resource 6) identified several SNPs
Fig. 1 Manhattan plot depicting the strength of association between
breast cancer risk in BRCA1 mutation carriers and all imputed and
genotyped SNPs located across the 11q22.3 locus bound by hg19
coordinates chr11:107990104_108173189. Directly genotyped SNPs
are represented as triangles and imputed SNPs (r2[ 0.3,
MAF[ 0.02) are represented as circles. The linkage disequilibrium
(r2) for the most strongly associated genotyped SNP with each SNP
was computed based on subjects of European ancestry that were
included in the 1000 Genome Mar 2012 EUR release. Pairwise r2
values are plotted using a red scale, where white and red means
r2 = 0 and 1, respectively. SNPs are plotted according to their
chromosomal position: physical locations are based on the GRCh37/
hg19 map. SNP rs228606 was genotyped in the iCOGS array but was
not included in our original hypothesis of association with DAE. Gene
annotation is based on the NCBI RefSeq gene descriptors from the
UCSC genome browser
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with significant associations in BRCA1 mutation carriers at
the 11q22.3 locus (with SNP rs228595 as the most sig-
nificant, p = 7.38 9 10-6), and which were partly corre-
lated with the genotyped SNPs (r2\0.4, Fig. 1). After
imputation, we also found associations (albeit not statisti-
cally significant after multiple testing adjustments),
between one imputed SNP at locus 12p13 (rs2255390,
p = 5.0 9 10-4) and breast cancer risk for BRCA1 carri-
ers, and two SNPs and breast cancer risk for BRCA2 car-
riers, namely 6p22 (chr6:28226644:I, p = 9.0 9 10-4) and
8q11 (rs189286892, p = 2.0 9 10-4).
Ovarian cancer association analyses
Evidence of association with ovarian cancer risk (p\ 10-2)
was observed for six SNPs in BRCA1 mutation carriers and
three SNPs in BRCA2 mutation carriers (Table 3). The
strongest association with ovarian cancer risk in BRCA1
carriers was observed for rs12025623 located at 1p36.12
(p = 7 9 10-3) in an intron of the ALPL gene. Another
correlated variant (r2[0.7) on chromosome 1 was also
genotyped, namely rs1767429 (p = 9 9 10-3), which was
also located within ALPL. The strongest evidence of asso-
ciation with ovarian cancer risk in BRCA2 mutation carriers
was observed for rs2233025 (p = 5 9 10-3), located at
1p32.22 within the MAD2L2 gene. None of these associa-
tions remained statistically significant after multiple testing
adjustments. Imputed genotypes of SNPs in a region
encompassing ± 50 kb centered on each of the nine asso-
ciated variants did not identify stronger associations.
eQTL analysis in breast tissue
To identify the genes influenced via the observed associ-
ations with breast cancer at locus 11q22.3, eQTL analysis
was performed using gene expression data from tumor and
normal breast tissues (for detailed descriptions of datasets,
refer to Online Resource 4), and all genotyped as well as
imputed SNPs within a 1-Mb region on either side of the
most significant genotyped SNP. eQTL associations were
observed in both normal and tumor breast tissues in this
region, although none of those were correlated with our
most significant risk SNPs (Online Resource 7). The
strongest eQTL associations were observed in the breast
cancer tissue dataset BC241 for the SLC35F2 gene
(rs181187590, p = 1.4 9 10-5, r2 = 0.08, i.e., 8 % of the
variation in SLC35F2 expression was attributable to this
SNP). Other eQTLs observed in this dataset included
ELMOD1 (rs181187590, p = 1.3 9 10-4, r2 = 0.06),
EXPH5 (rs181187590, p = 3 9 10-4, r2 = 0.054), and
ATM (rs4987915, p = 3.7 9 10-4, r2 = 0.05). In The
Cancer Genome Atlas (TCGA) BC765 breast cancer
dataset, the strongest associations with gene expression
were observed for the non-coding RNA lLOC643923
(rs183293362, p = 2.3 9 10-4, r2 = 0.02), ATM
(rs4987924, p = 8.3 9 10-4, r2 = 0.015), and KDELC2
Table 3 Associations with ovarian cancer risk in BRCA1 and BRCA2 mutation carriers for SNPs observed at p\ 10-2
Locations Positions SNPs Nearest genes Unaffected
(number)
Affected
(number)
Unaffected
(MAF)
HR* (95 % CI) p values
BRCA1 mutation carriers
1p36.12 21,889,340 rs1767429 ALPL, RAP1GAP 12,765 2460 0.42 1.092 (1.024–1.164) 9 9 10-3
1p36.12 21,892,479 rs12025623 ALPL, RAP1GAP 12,789 2460 0.36 1.098 (1.027–1.173) 7 9 10-3
6p21.32 32,913,246 rs1480380 BRD2, HLA-DMB, HLA-
DMA
12,790 2462 0.07 1.178 (1.041–1.333) 9 9 10-3
10p12.1 27,434,716 rs788209 ANKRD26, YME1L1,
MASTL, ACBD5
12,754 2455 0.15 0.879 (0.804–0.961) 5 9 10-3
17p13.1 8,071,592 rs3027247 MIR3676, C17orf59,
AURKB, C17orf44,
C17orf68, PFAS
12,786 2461 0.29 0.905 (0.844–0.970) 5 9 10-3
17q22 53,032,425 rs17817865 MIR4315-1, TOM1L1,
COX11, STXBP4
12,790 2462 0.27 0.905 (0.842–0.971) 8 9 10-3
BRCA2 mutation carriers
1p32.22 11,735,652 rs2233025 MAD2L2, FBXO6 7574 631 0.18 0.777 (0.657–0.919) 5 9 10-3
9p13.3 35,055,669 rs595429 VCP, FANCG, c9orf131 7579 631 0.46 0.856 (0.758–0.964) 6 9 10-3
17q25.3 76,219,783 rs2239680 DHX29, SKIV2L2 7579 630 0.28 0.828 (0.722–0.948) 7 9 10-3
CI confidence interval, HR hazard ratio, MAF minor allele frequency, SNP single-nucleotide polymorphism
* Hazard ratio per allele (one degree of freedom) estimated from the retrospective likelihood analysis
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(rs4753834, p = 8.6 9 10-4, r2 = 0.015) loci. The eQTL
analysis performed for the TCGA normal breast tissue
dataset (NB93) showed an association between SNP
chr11:108075271:D and ACAT1 gene expression level
(p = 6.5 9 10-3, r2 = 0.08). No association was observed
in the normal breast tissue dataset NB116.
Functional annotation
In order to assess the potential functional role of the most
significant risk SNPs in the 11q22.3 region, ENCODE
chromatin biological features were evaluated in available
breast cells, namely HMECs, breast myoepithelial cells,
and MCF7 breast cancer cells. We observed some overlap
between features of interest and candidate SNPs within
the 11q22.3 region (Fig. 2). The most interesting variant
was rs228606, which overlapped a monomethylated
H3K4 mark in HMECs. Analysis of data from the
Roadmap Epigenomics project also showed overlap with
a monomethylated H3K4 mark and with an acetylated
H3K9 mark in primary breast myoepithelial cells. From
ChiA-PET data, chromosomal interactions were found in
the NPAT and ATM genes in MCF7 cells, located mainly
in the vicinity of the promoter regions of these genes,
which encompassed a strongly associated imputed SNP at
this locus, namely chr11:108098459_TAA_T. Lastly,
although super-enhancers and predicted enhancer–pro-
moter interactions mapped to the 11q22.3 locus in
HMECs, none overlapped with our top candidate SNPs
(Fig. 2).
Discussion
DAE is a common phenomenon in human genes, which
represents a new approach to identifying cis-acting mech-
anisms of gene regulation. It offers a new avenue for the
study of GWAS variants significantly associated with
various diseases/traits. Indeed, the majority of GWAS hits
localize outside known protein-coding regions [11, 12],
suggesting a regulatory role for these variants. In the pre-
sent study, we have assessed the association between 320
SNPs associated with DAE and breast/ovarian cancer risk
among BRCA1 and BRCA2 mutation carriers. Using this
approach, we found evidence of association for a region at
11q22.3, with breast cancer risk in BRCA1 mutation car-
riers. Analysis of imputed SNPs across a 185-kb region
(±50 kb from the center of each of the three genotyped
SNPs at this locus) revealed a set of five strongly correlated
SNPs that were significantly associated with breast cancer
risk. This region contains several genes including ACAT1,
NPAT, and ATM. ACAT1 (acetyl-CoA acetyltransferase 1)
encodes a mitochondrial enzyme that catalyzes the rever-
sible formation of acetoacetyl-CoA from two molecules of
acetyl-CoA. Defects in this gene are associated with
ketothiolase deficiency, an inborn error of isoleucine cat-
abolism [29]. NPAT (nuclear protein, co-activator of his-
tone transcription) is required for progression through the
G1 and S phases of the cell cycle, for S phase entry [30],
and for the activation of the transcription of histones H2A,
H2B, H3, and H4 [31]. NPAT germline mutations have
been associated with Hodgkin lymphoma [32]. Finally,
ATM (ataxia telangiectasia mutated) encodes an important
cell cycle checkpoint kinase that is required for cellular
response to DNA damage and for genome stability.
Mutations in this gene are associated with ataxia telang-
iectasia, an autosomal recessive disorder [33]. ATM is also
an intermediate-risk breast cancer susceptibility gene, with
rare heterozygous variants being associated with increased
risk of developing the disease [34]. Although several
studies have assessed the role of the most common ATM
variants in breast cancer susceptibility, the results obtained
are inconsistent [35]. A recent study had identified an
association between an ATM haplotype and breast cancer
risk in BRCA1 mutation carriers with a false discovery rate-
adjusted p value of 0.029 for overall association of the
haplotype [36]. Four of the five SNPs making up the
haplotype were almost perfectly correlated (r2[0.9) with
the three originally genotyped SNPs of the present study.
These SNPs were, however, only moderately correlated
(r2[0.4) with the most significant risk SNPs (p = 10-6),
identified later through imputation.
Although eQTL analysis has identified cis-eQTL asso-
ciations between several variants and ACAT1, ATM as well
bFig. 2 Functional annotation of the 11q22.3 locus. Upper panel
functional annotations using data from the ENCODE and NIH
Roadmap Epigenomics projects. From top to bottom, epigenetic
signals evaluated included DNase clusters in MCF7 cells and HMECs,
chromatin state segmentation by hidden Markov model (ChromHMM)
in HMECs, breast myoepithelial cells, and variant human mammary
epithelial cells (vHMECs), where red represents an active promoter
region, orange a strong enhancer, and yellow a poised enhancer (the
detailed color scheme of chromatin states is described in the UCSC
browser), and histone modifications in MCF7 and HMEC cell lines.
All tracks were generated by the UCSC genome browser (hg 19
release). Lower panel long-range chromatin interactions: from top to
bottom, ChiA-PET interactions for RNA polymerase II in MCF-7 cells
identified through ENCODE and 4D-genome. The ChiA-PET raw data
available from the GEO database under the following accession
(GSE33664, GSE39495) were processed with the GenomicRanges
package. Maps of mammary cell super-enhancer locations as defined
in Hnisz et al. [24] are shown in HMECs. Predicted enhancer–
promoter determined interactions in HMECs, as defined by the
integrated method for predicting enhancer targets (IM-PET), are
shown. The annotation was obtained through the Bioconductor
annotation package TxDb.Hsapiens.UCSC.hg19.knownGene. The
tracks have been generated using ggplot2 and ggbio library in R
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as other neighboring genes in both breast carcinoma and
normal breast tissues, none of these associations involved
the most significantly associated risk SNPs. Furthermore,
the correlation between eQTLs and the most significant
risk SNPs was weak. The lack of consistency between the
eQTL results and the allelic imbalance data originally used
for SNP selection in the design of the present study can
probably be explained by the differences between the cell
types used in these analyses. The list of allelic imbalance-
associated SNPs was selected from studies performed in
lymphoblastoid cell lines [15], primary skin fibroblasts
[13, 16], and primary monocytes [17], while eQTLs were
analyzed in breast carcinoma and normal breast tissue. This
tissue heterogeneity in the data sources used represents one
of the limitations of this study, although no such data were
available in mammary cells when this study was originally
designed.
The identification of a region at 11q22.3 that is associ-
ated specifically with breast cancer risk in BRCA1 mutation
carriers may explain why association studies performed
using breast cancer cases from the general population have
so far yielded conflicting results with regard to common
variants at this locus. The majority of tumors arising in
BRCA1 carriers show either low or absent ER expression,
while the majority of BRCA2-associated tumors are ER
positive, as in most sporadic cancers arising in the general
population. Large-scale studies using only ER-negative or
triple-negative (i.e., ER-, progesterone receptor-, and
HER2-negative) cases could therefore be helpful to con-
firm the association of this locus with breast cancer risk.
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